OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time.

OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

OPKO Health, Inc. ( OPK ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - Senior VP & CFO Gary Nabel - Chief Information Officer & Director Conference Call Participants Yvonne Briggs - LHA Investor Relations Maurice Raycroft - Jefferies LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.

OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time.

BURLINGTON, N.C. and MIAMI , Sept.